Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?

被引：2
|
作者：
Catanese, Silvia [1 ,2 ]
Lordick, Florian [2 ]
机构：
[1] Univ Pisa, Azienda Osped Univ Pisana AOUP, Dept Med Oncol, Pisa, Italy
[2] Univ Leipzig, Univ Canc Ctr Leipzig UCCL, Med Ctr, Dept Med Oncol Gastroenterol Hepatol Pulmonol & I, Leipzig, Germany
来源：
ANNALS OF TRANSLATIONAL MEDICINE | 2020年 / 8卷 / 24期
关键词：
2ND-LINE THERAPY; DOUBLE-BLIND; OPEN-LABEL; PHASE-III; SORAFENIB; MULTICENTER; CAMRELIZUMAB;
D O I：
10.21037/atm-20-4438
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Predicting the anti-PD1 response
    Kirsty Minton
    Nature Reviews Immunology, 2019, 19 : 414 - 415
  • [22] Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy
    Sun, Guangshun
    Liu, Hanyuan
    Zhao, Jie
    Zhang, Jinyu
    Huang, Tian
    Sun, Guoqiang
    Zhao, Siqi
    Zhang, Zihao
    Cao, Hengsong
    Rong, Dawei
    Kong, Xiangyi
    Ji, Qinghua
    Liu, Li
    Wang, Xuehao
    Tang, Weiwei
    Xia, Yongxiang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (12)
  • [23] Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
    Kang, Xindan
    Wang, Jing
    Kang, Xue
    Bai, Li
    BMC CANCER, 2023, 23 (01)
  • [24] Metabolomics reveals ascorbic acid inhibits ferroptosis in hepatocytes and boosts the effectiveness of anti-PD1 immunotherapy in hepatocellular carcinoma
    Sun, Guoqiang
    Liu, Chuan
    Lu, Zhengqing
    Zhang, Jinyu
    Cao, Hengsong
    Huang, Tian
    Dai, Mingrui
    Liu, Hanyuan
    Feng, Tingting
    Tang, Weiwei
    Xia, Yongxiang
    CANCER CELL INTERNATIONAL, 2024, 24 (01)
  • [25] Amplification of spatially isolated adenosine pathway by tumor–macrophage interaction induces anti-PD1 resistance in hepatocellular carcinoma
    Jia-Cheng Lu
    Peng-Fei Zhang
    Xiao-Yong Huang
    Xiao-Jun Guo
    Chao Gao
    Hai-Ying Zeng
    Yi-Min Zheng
    Si-Wei Wang
    Jia-Bin Cai
    Qi-Man Sun
    Ying-Hong Shi
    Jian Zhou
    Ai-Wu Ke
    Guo-Ming Shi
    Jia Fan
    Journal of Hematology & Oncology, 14
  • [26] Therapy Options after Failure of anti-PD1 Monotherapy: an Analysis of the ADOReg Melanoma Registry
    Weichenthal, M.
    Ugurel, S.
    Kaehler, K.
    Hauschild, A.
    Schadendorf, D.
    Leiter-Stoeppke, U.
    Satzger, I.
    Gutzmer, R.
    Welzel, J.
    Mohr, P.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 81 - 82
  • [27] Predictive value of prognostic nutritional index (PNI) in recurrent or unresectable hepatocellular carcinoma received anti-PD1 therapy
    Xindan Kang
    Jing Wang
    Xue Kang
    Li Bai
    BMC Cancer, 23
  • [28] Effectiveness of anti-PD-1 for hepatocellular carcinoma
    Liao, Rui
    LANCET ONCOLOGY, 2020, 21 (06): : E293 - E293
  • [29] HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy
    Salman, Shaima
    Meyers, David J.
    Wicks, Elizabeth E.
    Lee, Sophia N.
    Datan, Emmanuel
    Thomas, Aline M.
    Anders, Nicole M.
    Hwang, Yousang
    Lyu, Yajing
    Yang, Yongkang
    Jackson, Walter, III
    Dordai, Dominic
    Rudek, Michelle A.
    Semenza, Gregg L.
    JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (09):
  • [30] Cabozantinib enhances the efficacy and immune modulatory activity of anti-PD1 therapy in a syngeneic mouse model of hepatocellular carcinoma
    Esteban-Fabro, Roger
    Willoughby, Catherine E.
    Pique-Gili, Marta
    Peix, Judit
    Montironi, Carla
    Abril-Fornaguera, Jordi
    Torrens, Laura
    Pinyol, Roser
    Llovet, Josep M.
    JOURNAL OF HEPATOLOGY, 2020, 73 : S40 - S40
12345